Market Cap | 9.17M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | - | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -32.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -53.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | - | Quick Ratio | - | Shares Outstanding | 0.92B | 52W Low Chg | 82.00% |
Insider Own | 91.70% | ROA | - | Shares Float | - | Beta | - |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.01 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 169,801 | Target Price | - |
Oper. Margin | - | Earnings Date | Oct 4 | Volume | 105,242 | Change | 0.00% |
Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.